| | | | | | | | | | |
|
|
|
|
| Dockets Entered
On April 26, 2004
Table of Contents
|
|
|
|
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
|
|
| 1977N-0094
|
| OTC Internal Analgesic, Antipyretic & Antirheumatic Products
|
|
|
|
|
| 1997S-0162
|
| 30-Day Structure Function Claim Notification Letters Dietary
|
|
|
|
|
| 1999N-4282
|
| Biotechnology in the Year 2000 and Beyond; Public Meetings
|
|
|
|
|
| 2002D-0325
|
| Polyvinychloride using Plasticier di-(2-ethyhexyl)phthalate
|
|
|
|
|
| 2003D-0478
|
| Guidance on Marketed Unapproved Drugs Compliance Policy Guide
|
|
|
|
|
| 2003N-0267
|
| Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Studies for Licensed Biological Products; Status Reports
|
|
|
|
|
| 2003P-0555
|
| Maintain the Electroconvulsive Therapy Device in Class III for All Indications
|
|
|
|
|
| 2004D-0192
|
| Guidance for Industry: Acceptable Full-Length Donor History Questionnaire and Accompanying Materials for Using Screening Human Donors of Blood and Blood Components Draft Guidance
|
|
|
|
|
| 2004N-0161
|
| Agency Information Collection Activities: Proposed Collection; Comment Request; Information from U.S. Processors that Export to the European Community
|
|
|
|
|
| 2004Q-0180
|
| Qualified Health Claim (QHC): Lutein and Eye Diseases
|
|
|
|
|
| 1977N-0094
|
| OTC Internal Analgesic, Antipyretic & Antirheumatic Products
|
|
|
|
|
| SUP
52
Attachment
|
| London School of Hygiene & Tropical Medicine
|
| Vol #:
|
| 235
|
|
|
|
|
| 1997S-0162
|
| 30-Day Structure Function Claim Notification Letters Dietary
|
|
|
|
|
| LET
13791
|
| Phytomer Corporation
|
| Vol #:
|
| 116
|
|
|
|
|
| LET
13792
|
| Dolisos America, Inc.
|
| Vol #:
|
| 116
|
|
|
|
|
| LET
13793
|
| Pharmanex, LLC
|
| Vol #:
|
| 116
|
|
|
|
|
| LET
13794
|
| Holly Bayne, P.C.
|
| Vol #:
|
| 116
|
|
|
|
|
| 1999N-4282
|
| Biotechnology in the Year 2000 and Beyond; Public Meetings
|
|
|
|
|
| EMC 4201
|
| E. Lynch
|
| Vol #:
|
| 515
|
|
|
|
|
| EMC 4202
|
| L. Coleman
|
| Vol #:
|
| 515
|
|
|
|
|
| EMC 4203
|
| L. Coleman
|
| Vol #:
|
| 515
|
|
|
|
|
| 2002D-0325
|
| Polyvinychloride using Plasticier di-(2-ethyhexyl)phthalate
|
|
|
|
|
| EMC 165
|
| J. Benincasa
|
| Vol #:
|
| 3
|
|
|
|
|
| EMC 166
|
| J. Davenport
|
| Vol #:
|
| 3
|
|
|
|
|
| EMC 167
|
| J. Davenport
|
| Vol #:
|
| 515
|
|
|
|
|
| EMC 168
|
| J. Enwright
|
| Vol #:
|
| 515
|
|
|
|
|
| 2003D-0478
|
| Guidance on Marketed Unapproved Drugs Compliance Policy Guide
|
|
|
|
|
| C
68
|
| Branded Pharmaceutical Assn (BPA)
|
| Vol #:
|
| 5
|
|
|
|
|
| 2003N-0267
|
| Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Studies for Licensed Biological Products; Status Reports
|
|
|
|
|
| NAL
1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
|
|
| SS
1
|
| SUPPORTING STATEMENT
|
| Vol #:
|
| 1
|
|
|
|
|
| 2003P-0555
|
| Maintain the Electroconvulsive Therapy Device in Class III for All Indications
|
|
